No approved vaccine exists for Klebsiella pneumoniae yet. Outer membrane protein-K17 (OMPK17) is involved in K. pneumoniae pathogenesis. No information has been found about OMPK17 dominant epitopes in the literature. Therefore, this study aimed to predict both T cell and B cell epitopes of K. pneumoniae OMPK17 via immunoinformatics approaches. Both T cell (class-I and II) and B cell (linear and discontinuous) epitopes of OMPK17 were predicted. Several screening analyses were performed including clustering, immunogenicity, human similarity, toxicity, allergenicity, conservancy, docking, and structural/physicochemical suitability. The results showed that some regions of OMPK17 have more potential as epitopes. The most possible epitopes were found via several analyses including the selection of higher-scoring epitopes, the epitopes predicted with more tools, more immunogenic epitopes, the epitopes capable of producing interferon-gamma, the epitopes with more dissimilarity to human peptides, and non-toxic and non-allergenic epitopes. By comparing the best T cell and B cell epitopes, we reached a 25-mer peptide containing both T cell (class-I and class-II) and B cell (linear) epitopes and comprising appropriate physicochemical characteristics that are required for K. pneumoniae vaccine development. The in vitro/in vivo study of this peptide is recommended to clarify its actual efficiency and efficacy.
Keywords Epitope • Immunoinformatics• Klebsiella pneumoniae • Outer membrane protein-K17 • Physicochemical characteristics Abbreviations CPORT Consensus prediction of interface residues in transient complexes GQE Global Quality Estimate GRAVY Grand average of hydropathicity index HLA Human leukocyte antigen IFN-γ Inte rferon-gamma LQE Local Quality Estimate OMP Outer membrane protein OMPK17 Outer membrane protein-K17 pI Isoelectric pH QMEAN Qualitative model energy analysis SDAP Structural database of allergenic proteins * Mosayeb Rostamian